KRIBIOLISA™ Teprotumumab ELISA
Enzyme Immunoassay for the Quantitative Determination of Teprotumumab in serum and plasma.
Receive your quote directly from the manufacturer.
Introduction:
Teprotumumba is a humanized monoclonal antibody that targets Insulin-Like Growth Factor I receptor. (IGF-1R). It was approved by the FDA in 2020 for the treatment of thyroid eye disease. The IGF-1R, overexpressed by orbital fibroblasts and B / T cells in thyroid eye disease, playa central role in the formation of functional complexes that result in inflammation, edma and expansion of extraocular muscle and adipose tissue. Teprotumumab attenuates signalling initiated at the receptor, thereby blocking immune responses.
Intended Use:
The KRIBIOLISA™TM Teprotumumab ELISA is used as an analytical tool for quantitative determination of Teprotumumab (TEPEZZA) in human serum and plasma.
Principle:
HERV-W envelope protein is pre-coated onto microwells. Samples and standards are pipetted into microwells HERV-W envelope protein antibody (Teprotumumab) present in the sample are bound by the capture antibody. Then, an Anti-Human IgG conjugated to HRP is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of HERV-W envelope protein antibody in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
